Cytokine modulation of epidermal growth factor receptor expression on bladder cancer cells is not a major contributor to the antitumour activity of cytokines
| Autor: | Andrew Jackson, Anton B. Alexandroff, Keith James, Geoffrey D. Chisholm |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment Receptor expression Cell Interferon-gamma Epidermal growth factor Internal medicine Tumor Cells Cultured medicine Humans Epidermal growth factor receptor Receptor Protein Kinase C Carcinoma Transitional Cell biology Tumor Necrosis Factor-alpha Immunotherapy Recombinant Proteins Neoplasm Proteins ErbB Receptors Kinetics medicine.anatomical_structure Endocrinology Cytokine Urinary Bladder Neoplasms Oncology BCG Vaccine Cancer research biology.protein Cytokines Tumor necrosis factor alpha Interleukin-1 |
| Zdroj: | European Journal of Cancer. 31:2059-2066 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/0959-8049(95)00210-3 |
| Popis: | Epidermal growth factor is a potential mitogen for many different human tumours. Its effect is mediated via a bispecific receptor (EGFR), the expression of which correlates well with invasive disease. We investigated the modulation of EGFR by cytokines produced following bacillus Calmette Guerin (BCG)-immunotherapy. Our data demonstrate the IFN gamma, TNF alpha and IL-1 alpha can decrease the expression of EGFR on some bladder tumour cell lines. IFN gamma reduced EGFR expression on two of eight cell lines (RT4, SD). However, IL-1 and TNF did not share this activity. When cells were treated with a combination of all three cytokines, EGFR was decreased on three cell lines (RT4, RT112, SD) and furthermore, the change in the receptor expression was even more marked. Treatment with phorbol ester (thereby activating protein kinase C) resulted in rapid disappearance of the receptor from the cell surface. Interestingly, the decrease of EGFR expression did not require protein synthesis. Although the cytokines studied could down modulate EGFR, this only occurred on three out of eight cell lines; therefore, it is unlikely that the suppression of proliferative activity caused by cytokine-induced decrease of EGFR expression is central to the antitumour action of BCG therapy, but in a proportion of tumours this mechanism may be involved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect